# Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

> **NCT04824352** · PHASE2 · SUSPENDED · sponsor: **Peking University People's Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Effect of Drug
- Toxicity, Drug

## Interventions

- **DRUG:** apatinib

## Key facts

- **NCT ID:** NCT04824352
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-04-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 44 (ESTIMATED)
- **Why stopped:** Because we then tried another trial with radomised design.
- **Last updated:** 2024-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04824352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04824352, "Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04824352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*